About: http://data.cimple.eu/news-article/831ddcaffe838c89b440b0a349d3ec005e769e4bb1442df9eca85028

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/831ddcaffe838c89b440b0a349d3ec005e769e4bb1442df9eca85028 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	An arthritis drug that was being closely watched for its potential use against COVID-19 has delivered disappointing results in clinical trials, its makers said Monday. Kevzara, which is made by Regeneron and Sanofi, does not attack the novel coronavirus but instead inhibits an abnormal immune response called a "cytokine storm" that causes the lungs of the sickest patients to become inflamed, leaving them fighting for their lives on ventilators. An early small study in China had appeared promising, but the drug showed no benefit over a placebo in a larger US study of 276 patients with "severe" disease -- that is to say, those requiring oxygen but not ventilators. There was, however, a ray of hope for those who were "critical," defined as needing mechanical ventilation or high-flow oxygenation. In this group, 44 were on a placebo, 94 were given a low dose and 88 were given a high dose. Fifty-five percent of patients on the placebo died by the end of the study period, compared with 46 percent on the lower dose and 32 percent on the high dose. The trial will continue among this critical group. "We await results of the ongoing Phase 3 trial to learn more about COVID-19, and better understand whether some patients may benefit from Kevzara treatment," said George Yancopoulos, Regeneron's president and co-founder. The company is separately developing an antibody cocktail that will directly target the virus and that it hopes to advance into human trials by June. These antibodies are being acquired by infecting mice that have had their immune systems genetically modified to become human-like. Regeneron has previously used this system to develop a treatment that proved effective against Ebola. ia/to
schema:headline	Closely watched arthritis drug disappoints in COVID-19 trial
schema:mentions	Mechanical ventilation Cytokine release syndrome Oxygen therapy Cocktail Immune response USA Gymnastics Arthritis Placebo Genetic engineering Antibody Ebola virus disease Ia (cuneiform) Virus China Coronavirus Coronavirus disease 2019 George Yancopoulos Sarilumab Monoclonal antibody Sanofi
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-04-28 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	86 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software